Malignancy cell heterogeneity is a common feature – both between individuals diagnosed with the same malignancy and within an individual patient’s tumor – and prospects to BMS-794833 widely different response rates to malignancy therapies and the potential for the emergence of drug resistance. BMS-794833 restorative genes under multi-tiered rules to target tumor heterogeneity including heterogeneity… Continue reading Malignancy cell heterogeneity is a common feature – both between individuals